Brain imaging and cognitive predictors of stroke and alzheimer disease in the framingham heart study

Stroke

Volumn 44, Issue 10, 2013, Pages 2787-2794

  Weinstein, Galit ^a,b   Beiser, Alexa S ^a,b,c   Decarli, Charles ^d   Au, Rhoda ^a,b   Wolf, Philip A ^a,b   Seshadri, Sudha ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Cognition; Magnetic resonance imaging; Stroke

Indexed keywords

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN INFARCTION; BRAIN SIZE; CEPHALOMETRY; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; COGNITION; COHORT ANALYSIS; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEMORY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGENY; SECONDARY ANALYSIS; SKULL; VOLUMETRY; WHITE MATTER;

ALZHEIMER DISEASE; COGNITION; MAGNETIC RESONANCE IMAGING; STROKE;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; COGNITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84888328724     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.000947     Document Type: Article

References (53)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010, 121:e46-e215.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011, 377:1019-1031.
3. Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, et al. Dementia after stroke: The Framingham Study. 2004, 35:1264-1268.
4. Jin YP, Di Legge S, Ostbye T, Feightner JW, Hachinski V. The reciprocal risks of stroke and cognitive impairment in an elderly population. Alzheimers Dement. 2006, 2:171-178.
5. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004, 35(11 suppl 1):2620-2622.
6. Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology. 2006, 67:441-445.
7. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000, 57:808-813.
8. Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005, 65:1227-1231.
9. Kaye JA, Swihart T, Howieson D, Dame A, Moore MM, Karnos T, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology. 1997, 48:1297-1304.
10. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, et al. Brain structural alterations before mild cognitive impairment. Neurology. 2007, 68:1268-1273.
11. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, et al, Alzheimer's Disease Neuroimaging Initiative. Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology. 2011, 259:844-851.
12. Tondelli M, Wilcock GK, Nichelli P, De Jager CA, Jenkinson M, Zamboni G. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. Neurobiol Aging. 2012, 33:825.
13. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation. 2011, 123:e18-e209.
14. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the Framingham Study. Stroke. 1991, 22:312-318.
15. Knopman DS, Penman AD, Catellier DJ, Coker LH, Shibata DK, Sharrett AR, et al. Vascular risk factors and longitudinal changes on brain MRI: The ARIC study. Neurology. 2011, 76:1879-1885.
16. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D'Agostino RB, et al. Stroke risk profile predicts white matter hyperintensity volume: The Framingham Study. Stroke. 2004, 35:1857-1861.
17. Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Beiser A, Au R, et al. Framingham stroke risk profile and lowered cognitive performance. Stroke. 2004, 35:404-409.
18. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: The Framingham Study. Am J Public Health Nations Health. 1951, 41:279-281.
19. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975, 4:518-525.
20. Au R, Seshadri S, Wolf PA, Elias M, Elias P, Sullivan L, et al. New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res. 2004, 30:333-358.
21. Farmer ME, White LR, Kittner SJ, Kaplan E, Moes E, McNamara P, et al. Neuropsychological test performance in Framingham: A descriptive study. Psychol Rep. 1987, 60(3 pt 2):1023-1040.
22. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D'Agostino RB, et al. Stroke risk profile predicts white matter hyperintensity volume: The Framingham Study. Stroke. 2004, 35:1857-1861.
23. De Carli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging. 2005, 26:491-510.
24. Seshadri S, Wolf PA, Beiser A, Elias MF, Au R, Kase CS, et al. Stroke risk profile, brain volume, and cognitive function: The Framingham Offspring Study. Neurology. 2004, 63:1591-1599.
25. De Carli C, Maisog J, Murphy DG, Teichberg D, Rapoport SI, Horwitz B. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr. 1992, 16:274-284.
26. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol. 2008, 65:642-649.
27. De Carli C, Miller BL, Swan GE, Reed T, Wolf PA, Garner J, et al. Predictors of brain morphology for the men of the NHLBI twin study. Stroke. 1999, 30:529-536.
28. Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, et al. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997, 49:1498-1504.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984, 34:939-944.
30. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004, 256:183-194.
31. Luck T, Luppa M, Briel S, Riedel-Heller SG. Incidence of mild cognitive impairment: A systematic review. Dement Geriatr Cogn Disord. 2010, 29:164-175.
32. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003, 60:1385-1389.
33. Manly JJ, Bell-McGinty S, Tang MX, Schupf N, Stern Y, Mayeux R. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol. 2005, 62:1739-1746.
34. Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012, 176:473-481.
35. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the Framingham Study. Stroke. 1991, 22:312-318.
36. Truelsen T, Lindenstrøm E, Boysen G. Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study. Stroke. 1994, 25:802-807.
37. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: Adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994, 25:40-43.
38. Elkins JS, Knopman DS, Yaffe K, Johnston SC. Cognitive function predicts first-time stroke and heart disease. Neurology. 2005, 64:1750-1755.
39. Wiberg B, Lind L, Kilander L, Zethelius B, Sundelöf JE, Sundström J. Cognitive function and risk of stroke in elderly men. Neurology. 2010, 74: 379-385.
40. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol. 2006, 63:246-250.
41. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002, 1:426-436.
42. Debette S, Beiser A, De Carli C, Au R, Himali JJ, Kelly-Hayes M, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: The Framingham Offspring Study. Stroke. 2010, 41:600-606.
43. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010, 341:c3666.
44. Poels MM, Steyerberg EW, Wieberdink RG, Hofman A, Koudstaal PJ, Ikram MA, et al. Assessment of cerebral small vessel disease predicts individual stroke risk. J Neurol Neurosurg Psychiatry. 2012, 83:1174-1179.
45. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
46. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al, Global prevalence of dementia: A Delphi consensus study. Lancet. 2005, 366:2112-2117.
47. Kloppenborg RP, Nederkoorn PJ, Grool AM, Vincken KL, Mali WP, Vermeulen M, et al, Cerebral small-vessel disease and progression of brain atrophy: The SMART-MR study. Neurology. 2012, 79:2029-2036.
48. Enzinger C, Fazekas F, Matthews PM, Ropele S, Schmidt H, Smith S, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005, 64:1704-1711.
49. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, et al. White matter lesion progression, brain atrophy, and cognitive decline: The Austrian stroke prevention study. Ann Neurol. 2005, 58:610-616.
50. Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ. Multiple cognitive deficits during the transition to Alzheimer's disease. J Intern Med. 2004, 256:195-204.
51. Rapp MA, Reischies FM. Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE). Am J Geriatr Psychiatry. 2005, 13:134-141.
52. Rubin EH, Storandt M, Miller JP, Kinscherf DA, Grant EA, Morris JC, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol. 1998, 55:395-401.
53. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc. 2008, 14:266-278.